Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Receivables (2016 - 2025)

UroGen Pharma (URGN) has disclosed Receivables for 7 consecutive years, with $33.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 62.95% year-over-year to $33.1 million, compared with a TTM value of $33.1 million through Dec 2025, up 62.95%, and an annual FY2025 reading of $33.1 million, up 62.95% over the prior year.
  • Receivables was $33.1 million for Q4 2025 at UroGen Pharma, up from $19.7 million in the prior quarter.
  • Across five years, Receivables topped out at $33.1 million in Q4 2025 and bottomed at $6.3 million in Q1 2021.
  • Average Receivables over 5 years is $15.1 million, with a median of $13.5 million recorded in 2023.
  • The sharpest move saw Receivables skyrocketed 2266.17% in 2021, then decreased 13.59% in 2025.
  • Year by year, Receivables stood at $11.7 million in 2021, then grew by 8.42% to $12.7 million in 2022, then grew by 21.56% to $15.4 million in 2023, then soared by 31.46% to $20.3 million in 2024, then skyrocketed by 62.95% to $33.1 million in 2025.
  • Business Quant data shows Receivables for URGN at $33.1 million in Q4 2025, $19.7 million in Q3 2025, and $19.6 million in Q2 2025.